
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx Inc has demonstrated significant financial growth with Q4 2024 net sales for IBSRELA reaching $53.8 million, representing a 32.5% increase from Q3 2024, and XPHOZAH sales totaling $57.2 million, marking an 11.1% quarterly growth, contributing to a total of $160.9 million in its first full year of XPHOZAH sales. The company is optimistic about future sales projections, with estimated 2025 net sales for IBSRELA set at $241.2 million and a projected annual growth of approximately 52% - 58%, alongside a moderate growth rate for XPHOZAH sales. Ardelyx is also implementing new patient outreach initiatives and expanding its sales team, enhancing access to treatments and potentially supporting long-term revenue growth.
Bears say
Ardelyx Inc. faces several significant challenges that contribute to a negative outlook for its stock, particularly with respect to its product XPHOZAH; total weekly scripts are projected to remain stagnant at around 750, raising concerns about its market penetration and growth trajectory. The company reported a substantial FY2024 net loss of $39.1 million, accompanied by high operating costs, notably $258.7 million in SG&A expenses, which could hinder financial sustainability and viability going forward. Furthermore, potential risks such as market size limitations, competition, and the possibility of regulatory issues or clinical trial failures introduce substantial uncertainty regarding the future performance of its products, exacerbating the volatility typically associated with biotech investments.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares